KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Restructuring Costs (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Restructuring Costs data on record, last reported at $2.5 million in Q4 2025.

  • For Q4 2025, Restructuring Costs rose 401.01% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $4.2 million, up 78.68%, while the annual FY2025 figure was $4.2 million, 78.68% up from the prior year.
  • Restructuring Costs reached $2.5 million in Q4 2025 per AMRX's latest filing, up from $143000.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $7.3 million in Q4 2021 and bottomed at $82000.0 in Q2 2023.
  • Average Restructuring Costs over 5 years is $990722.2, with a median of $501500.0 recorded in 2023.
  • Peak YoY movement for Restructuring Costs: plummeted 98.51% in 2022, then soared 401.01% in 2025.
  • A 5-year view of Restructuring Costs shows it stood at $7.3 million in 2021, then tumbled by 98.51% to $109000.0 in 2022, then grew by 4.59% to $114000.0 in 2023, then skyrocketed by 332.46% to $493000.0 in 2024, then skyrocketed by 401.01% to $2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Restructuring Costs were $2.5 million in Q4 2025, $143000.0 in Q3 2025, and $1.0 million in Q2 2025.